In vivo evaluation of neutron capture therapy effectivity using calcium phosphate-based nanoparticles as Gd-DTPA delivery agent

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 4, 2016, Pages 767-775

  Dewi, Novriana ^a   Mi, Peng ^b,c,d   Yanagie, Hironobu ^a,e,f   Sakurai, Yuriko ^e   Morishita, Yasuyuki ^d   Yanagawa, Masashi ^g   Nakagawa, Takayuki ^h   Shinohara, Atsuko ⁱ   Matsukawa, Takehisa ^j   Yokoyama, Kazuhito ^j   Cabral, Horacio ^a   Suzuki, Minoru ^k   Sakurai, Yoshinori ^k   Tanaka, Hiroki ^k   Ono, Koji ^k   Nishiyama, Nobuhiro ^b,c   Kataoka, Kazunori ^a,b,d   Takahashi, Hiroyuki ^a,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b Kawasaki Institute of Industry Promotion   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^f MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^g OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ Seisen University   (Japan)

^j JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k KYOTO UNIVERSITY   (Japan)

more..

Author keywords

Calcium phosphate; Gadolinium; Nanoparticles; Neutron capture therapy

Indexed keywords

CALCIUM PHOSPHATE NANOPARTICLE; GADOLINIUM PENTETATE; NANOPARTICLE; UNCLASSIFIED DRUG; CALCIUM PHOSPHATE; CONTRAST MEDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; HISTOPATHOLOGY; IN VIVO STUDY; MOUSE; NEUTRON; NEUTRON CAPTURE THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; COLONIC NEOPLASMS; EVALUATION STUDY; FEMALE; HUMAN; INJECTION; JAPAN; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANIMALS; CALCIUM PHOSPHATES; COLONIC NEOPLASMS; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; GADOLINIUM DTPA; HUMANS; INJECTIONS; JAPAN; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; NEUTRON CAPTURE THERAPY; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84961129755     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-2085-0     Document Type: Article

References (41)

1. Aime S, Caravan P (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 30(6):1259–1267
2. Barth RF, Coderre JA, Vicente MGH, Blue TE (2005) Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 11:3987–4002
3. Brugger RM, Shih JA (1989) Evaluation of gadolinium-157 as a neutron capture therapy agent. Strahlenther Onkol 165:153–156
4. Cerullo N, Bufalino D, Daquino G (2009) Progress in the use of gadolinium for NCT. Appl Radiat Isot 67:S157–S160
5. Chadha M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, Liu HB, Wielopolski L, Chanana AD (1998) Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys 40(4):829–834
6. De Stasio G, Casalbore P, Pallini R et al (2001) Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res 61:4272–4277
7. De Stasio G et al (2005) Are gadolinium contrast agents suitable for gadolinium neutron capture therapy? Neurol Res 27:387–398
8. Dewi N, Yanagie H, Zhu H et al (2013) Tumor growth suppression by gadolinium–neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent. Biomed Pharmacother 67:451–457
9. Dorozhkin SV, Epple M (2002) Biological and medical significance of calcium phosphate. Angew Chem Int Ed Engl 41(17):3130–3146
10. Epple M et al (2010) Application of calcium phosphate nanoparticles in biomedicine. J Mater Chem 20:18–23
11. Fuwa N, Suzuki M, Sakurai Y et al (2008) Treatment results of boron neutron capture therapy using intra-arterial administration of boron compounds for recurrent head and neck cancer. Br J Radiol 81:749–752
12. Gerweck LE, Seetharaman K (1996) Cellular pH gradient in tumor versus normal tissue. Cancer Res 56:1194–1198
13. Goorley T, Nikjoo H (2000) Electron and photon spectra for three gadolinium-based cancer therapy approaches. Radiat Res 154:556–563
14. Hambley TW, Hait WN (2009) Is anticancer drug development heading in the right direction? Cancer Res 69:1259–1262
15. Harms AA, Norman GR (1972) The role of internal conversion electrons in gadolinium-exposure neutron imaging. J Appl Phys 43(7):3209–3212
16. Henriksson R, Capala J, Michanek A et al (2008) Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high dose of boronophenylalanine (BPA). Radiother Oncol 88:183–191
17. Ichikawa H, Uneme T, Andoh T, Arita Y, Fujimoto T, Suzuki M et al (2014) Gadolinium-loaded chitosan nanoparticles for neutron-capture therapy: influence of micrometric properties of the nanoparticles on tumor-killing effect. Appl Radiat Isot 88:109–113
18. Joensuu H, Kankaanranta L, Seppälä T et al (2003) Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J Neurooncol 62:123–134
19. Kassis AI, Adelstein SJ, Haydock C, Sastry KSR, McElvany KD, Welch MJ (1982) Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res 90:362–373
20. Kobayashi H, Watanabe R, Choyke PL (2014) Improving conventional enhanced permeability and retention (EPR) effects; What is the appropriate target? Theranostics 4(1):81–89
21. Le UM, Cui Z (2006) Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int J Pharm 312:105–112
22. Locher GL (1936) Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol Radium Ther 36:1–13
23. Longmire MR, Ogawa M, Choyke PL, Kobayashi H (2011) Biologically optimized nanosized molecules and particles: more than just size. Bioconjug Chem 22:993–1000
24. 157Gd neutron capture. Pigment Cell Res 2:330–332
25. Masiakowski JT, Horton JL, Peters LJ (1992) Gadolinium neutron capture therapy for brain tumors: a computer study. Med Phys 19:1277–1284
26. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the anti-tumor agent smancs. Cancer Res 46:6387–6392
27. Mi P, Kokuryo D, Cabral H, Kumagai M, Nomoto T, Aoki I, Terada Y, Kishimura A, Nishiyama N, Kataoka K (2014) Hydrothermally synthesized PEGylated calcium phosphate nanoparticles incorporating Gd-DTPA for contrast enhanced MRI diagnosis of solid tumors. J Controlled Release 174:63–71
28. Mi P, Dewi N, Yanagie H, Kokuryo D, Suzuki M, Sakurai Y, Li Y, Aoki I, Ono K, Takahashi H, Cabral H, Nishiyama N, Kataoka K (2015) Hybrid calcium phosphate-polymeric micelles incorporating gadolinium chelates for imaging-guided gadolinium neutron capture tumor therapy. ACS Nano. doi:10.1021/acsnano.5b00532
29. Rey C, Combes C, Drouet C, Sfihi H, Barroug A (2007) Physico-chmeical properties of nanocrystalline apatites: implications for biominerals and biomaterials. Mater Sci Eng 27:198–205
30. Ruoslahti E, Sangeeta NB, Michael JS (2010) Targeting of drugs and nanoparticles to tumor. J Cell Biol 188(6):759–768
31. Shih JL, Brugger RM (1992) Gadolinium as neutron capture therapy agent. Med Phys 19(3):733–744
32. Tokumitsu H et al (2000) Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor. Cancer Lett 150:177–182
33. Tung M (1998) Calcium phosphates: structure, composition, solubility, and stability. In: Amjad Z (ed) Calcium phosphates in biological and industrial systems. Kluwer Academic Publishers, Boston, pp 1–19
34. Watanabe T, Ichikawa H, Fukumori Y (2002) Tumor accumulation of gadolinium in lipid-nanoparticles intravenously injected for neutron-capture therapy of cancer. Eur J Pharm Biopharm 54:119–124
35. Weinmann HJ, Brasch RC, Press WR, Wesbey GE (1984) Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 142:619–624
36. Yamamoto T, Matsumura A, Nakai K, Shibata Y, Endo K, Sakurai F, Kishi T, Kumada H, Yamamoto K, Torii Y (2004) Current clinical results of the Tsukuba BNCT trial. Appl Radiat Isot 61(5):1089–1093
37. Yanagie H, Tomita T, Kobayashi H, Fujii Y, Takahashi T, Hasumi K, Nariuchi H, Sekiguchi M (1991) Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model. Br J Cancer 63(4):522–526
38. Yanagie H, Ogata A, Sugiyama H, Eriguchi M, Takamoto S, Takahashi H (2008) Application of drug delivery system to boron neutron capture therapy for cancer. Expert Opin Drug Deliv 5(4):427–443
39. Yasui L, Owens K (2012) Necrosis is not induced by gadolinium neutron capture in glioblastoma multiforme cells. Int J Radiat Biol 88:980–990
40. Yasui L et al (2008) Gadolinium neutron capture in glioblastoma multiforme cells. Int J Radiat Biol 84:1130–1139
41. Yuan F (1998) Transvascular drug delivery in solid tumors. Semin Radiat Oncol 8:164–175